Methods for Producing a Non Human Model for Aortic Aneurysm

The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.

Tr1 cells for use in atherosclerosis

The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.

Use of il-18 inhibitors for treatment and/or prevention of peripheral vascular diseases

The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.

USE OF IL-18 INHIBITORS FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL VASCULAR DISEASES

The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.

Methods for Predicting Cardiovascular Mortality Risk

The present invention relates to a method for predicting cardiovascular mortality risk in a patient, comprising determining the level of endothelial microparticles in a blood sample obtained from said patient.

Methods for Predicting Cardiovascular Mortality Risk

The present invention relates to a method for predicting cardiovascular mortality risk in a patient, comprising determining the level of endothelial microparticles in a blood sample obtained from said patient. 1. A method for predicting cardiovascular mortality risk in a patient , comprising the steps of i) determining a level of endothelial microparticles in a blood sample obtained from said patient; and ii) comparing the level of endothelial microparticles with a predetermined value.2. (canceled)3. The method according to wherein said blood sample is a plasma sample.4. The method according to wherein the patient is or is not previously diagnosed with a cardiovascular disease.5. The method according to claim 4 , wherein the patient is suffering from a disease associated with a high risk of cardiovascular complications selected from the group consisting of chronic kidney disease and end stage renal disease.6. A method for monitoring the impact of a treatment administered to a patient on cardiovascular mortality risk claim 4 , comprising determining a level of endothelial microparticles in a blood sample obtained from said patient.7. The method according to claim 6 , wherein said method further comprises a step of comparing the level of endothelial microparticles with a predetermined value.8. The method according to claim 7 , wherein said predetermined value is the cardiovascular risk determined by determining a level of endothelial microparticles in a blood sample obtained from said patient before administering the treatment.9. A method for predicting a major adverse cardiovascular event (MACE) in a patient claim 7 , comprising determining a level of endothelial microparticles in a blood sample obtained from said patient.10. The method according to wherein said method further comprises a step of comparing the level of endothelial microparticles with a predetermined value.11. The method according to wherein said MACE is selected from the group consisting of death ...

Method for use in the treatment of aneurysm

The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression.

A B Cell Depleting Agent for the Treatment of Atherosclerosis

The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis. 1. A method for treating myocardial infarction in a subject in need thereof , comprising the step ofadministering a sufficient quantity of an anti-human CD20 antibody to said subject within one hour of the myocardial infarction, wherein said anti-human CD20 antibody depletes or destroys mature B cells or interferes with B cell functions in said subject and increases fractional shortening.2. The method of claim 1 , wherein said anti-human CD20 antibody is a full length anti-CD20 antibody.3. The method of claim 1 , wherein the myocardial infarction is a ST segment elevation myocardial infarction. The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.Atherosclerosis is the most common cause of death in western societies and is predicted to become the leading cause of cardiovascular disease in the world within two decades.Atherosclerosis contributes to the development of atherosclerotic vascular diseases (AVD) which may affect the coronary arteries (causing ischaemic heart disease), the cerebral circulation (causing cerebrovascular disease), the aorta (producing aneurysms that are prone to thrombosis and rupture) and peripheral blood vessels, typically the legs (causing peripheral vascular disease and intermittent claudication). Ischaemic heart disease (IHD) includes angina (chest pain caused by insufficient blood supply to cardiac muscle) and myocardial infarction (death of cardiac muscle) and cerebrovascular disease includes stroke and transient ischaemic attacks. One in three men and one in four women will die from IHD and the death rate for IHD was 58 per 100,000 in 1990.Atherosclerotic plaques begin as fatty streaks underlying the endothelium of large arteries. Recruitment of ...

Use of adipose tisue cells for initiating the formation of a fuctional vascular network

The invention relates to the use of cells of a medullary or extra-medullary white adipose tissue, in particular of an extra-medullary stromal vascular fraction (SVF) and/or mature dedifferentiated adipocytes of any origin for initiating the formation of a functional vascularisation.

Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis

The present invention relates to the prevention or treatment of atherosclerosis, using an IL-17 polypeptide and pharmaceutical compositions thereof.

Tri1 Cells for Use in Atherosclerosis

The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD 4 + T lymphocyte population of said mammal.

Methods for producing a non human model for aortic aneurysm

The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.

Method and Pharmaceutical Composition for use in the Treatment and Prediction of Myocardial Infarction

The present invention relates to a method for predicting the survival time of a patient suffering of myocardial infarction or the recurrence of a myocardial infarction in a patient who has suffered from a myocardial infarction comprising the steps consisting of i) determining the expression level of BAFF in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value. 1. A method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction in a patient who has suffered from a myocardial infarction comprising the steps of i) determining the expression level of B cell activating factor (BAFF) in a sample from said patient , ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.2. The method according to the wherein the patient is a non-lupic patient.3. The method according to claim 1 , wherein said sample is selected from the group consisting of blood claim 1 , plasma claim 1 , serum claim 1 , lymph and cardiac tissue.4. A method of improving heart function in a subject in heed thereof claim 1 , comprising a step ofadministering to the subject a therapeutically effective amount of a compound which inhibits the binding of B ...

COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS

The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least one epitope to said subject induces a specific regulatory immune response, preferably a Treg response.

A B Cell Depleting Agent for the Treatment of Atherosclerosis

The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis. 17-. (canceled)8. A method for treating myocardial infarction in a subject in need thereof , comprising the step of administering a sufficient quantity of a B cell depleting agent to said subject , said B cell depleting agent depletes or destroys B cells or interferes with B cell functions in said subject and increases fractional shortening.9. The method of wherein said B cell depleting agent is or includes an anti-CD20 antibody.10. The method of wherein said depleting agent is a fusion protien.11. The method of wherein said deplating agent is an antibody conjugated to a cytotoxic agent to said B cell.12. The method of wherein said depleting agent is a full length anti-CD20 antibody. The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.Atherosclerosis is the most common cause of death in western societies and is predicted to become the leading cause of cardiovascular disease in the world within two decades.Atherosclerosis contributes to the development of atherosclerotic vascular diseases (AVD) which may affect the coronary arteries (causing ischaemic heart disease), the cerebral circulation (causing cerebrovascular disease), the aorta (producing aneurysms that are prone to thrombosis and rupture) and peripheral blood vessels, typically the legs (causing peripheral vascular disease and intermittent claudication). Ischaemic heart disease (IHD) includes angina (chest pain caused by insufficient blood supply to cardiac muscle) and myocardial infarction (death of cardiac muscle) and cerebrovascular disease includes stroke and transient ischaemic attacks. One in three men and one in four women will die from IHD and the death rate for IHD was 58 per 100,000 in 1990.Atherosclerotic ...

Cardiovascular Prognostic and Diagnostic Marker

The present invention relates to a method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, comprising: determining the sPLA2 activity of said patient, comparing said activity to a predetermined value, a higher sPLA2 activity of said patient as compared to said predetermined value being indicative of an increased risk of mortality or of a cardiac and/or vascular event.

Use of Measles Virus Nucleoprotein for Treating Atherosclerosis

The present invention relates to the use of the measles virus nucleoprotein (NP), fragments or variants thereof for the treatment and/or the prevention of atherosclerosis.

USE OF SPLA2 ACTIVITY FOR THE DIAGNOSIS OF A CARDIOVASCULAR EVENT

A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:—determining the sPLA2 activity of the patient as a first risk marker—determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level—determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed.

Combination of sPLA2 activity and oxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event

The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease.

Method of predicting survival time in myocardial infarction patients by measuring BAFF levels

The present invention relates to a method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction. The method comprises the steps of i) determining the expression level of BAFF in a sample from the patient, ii) comparing the expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.

Use Of Adipose Tissue Cells For Initiating The Formation Of A Functional Vascular Network

This invention relates to the use of cells of a medullary or extra-medullary white adipose tissue, in particular of an extra-medullary stromal vascular fraction (SVF) and/or mature dedifferentiated adipocytes of any origin for initiating the formation of a functional vascularisation.

COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT

The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.

Use of sPLA2 activity for the diagnosis of a cardiovascular event

A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:determining the sPLA2 activity of the patient as a first risk markerdetermining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL leveldetermining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed.

Use of IL-18BP for treatment of peripheral vascular diseases

The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.

Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis

The invention relates to the use of an IL-18 inhibitor for the manufacture of a medicament for the treatment and/or prevention of atherosclerosis.

COMBINATION OF SPLA2 ACTIVITY AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT

The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease.

Combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event

A method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, includes: measuring, in a sample obtained from the subject, at least two cardiovascular risk factors: a) sPLA2 activity and b) oxidized phospholipids on apolipoprotein B-100 particles (OxPL/apoB), combining the measurements, the combined value of sPLA2 activity and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.

A B Cell Depleting Agent for the Treatment of Atherosclerosis

The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.

Composition for the treatment of atherosclerosis

The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least one epitope to said subject induces a specific regulatory immune response, preferably a Treg response.

A B Cell Depleting Agent for the Treatment of Atherosclerosis

The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis. 1. A method for treating myocardial infarction in a subject in need thereof , comprising the step ofadministering a sufficient quantity of an anti-human CD20 antibody to said subject within one hour of the myocardial infarction, wherein said anti-human CD20 antibody depletes or destroys mature B cells or interferes with B cell functions in said subject and increases fractional shortening.2. The method of claim 1 , wherein said anti-human CD20 antibody is a full length anti-CD20 antibody.3. The method of claim 1 , wherein the myocardial infarction is a ST segment elevation myocardial infarction. The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.Atherosclerosis is the most common cause of death in western societies and is predicted to become the leading cause of cardiovascular disease in the world within two decades.Atherosclerosis contributes to the development of atherosclerotic vascular diseases (AVD) which may affect the coronary arteries (causing ischaemic heart disease), the cerebral circulation (causing cerebrovascular disease), the aorta (producing aneurysms that are prone to thrombosis and rupture) and peripheral blood vessels, typically the legs (causing peripheral vascular disease and intermittent claudication). Ischaemic heart disease (IHD) includes angina (chest pain caused by insufficient blood supply to cardiac muscle) and myocardial infarction (death of cardiac muscle) and cerebrovascular disease includes stroke and transient ischaemic attacks. One in three men and one in four women will die from IHD and the death rate for IHD was 58 per 100,000 in 1990.Atherosclerotic plaques begin as fatty streaks underlying the endothelium of large arteries. Recruitment of ...

METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT

The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject. 1. An in vitro method for predicting the risk of a cardiovascular event in a subject , said method comprising the steps of contacting the blood sample with a binding partner that is specific for the IL-17, wherein the step of contacting forms an IL-17-binding partner complex, and', 'detecting the IL-17-binding partner complex as a measure of the level of IL-17; and, 'i) measuring a level of IL-17 in a blood sample obtained from said subject by'}ii) comparing the level measured at step i) with a reference value, wherein a difference between said IL-17 level and said reference value is indicative of a risk of having a cardiovascular event.2. The in vitro method according to which further comprises a step of measuring a level of soluble vascular cell adhesion molecule-1 (sVCAM-1) in the blood sample obtained from the subject.3. The in vitro method according to wherein a Th17 blocker treatment was administered to said subject.4. A kit for performing the method according to which comprises means for measuring the level of IL-17 and means for measuring the levels of sVCAM-1 in a blood sample.5. The method of claim 1 , wherein the binding partner is an antibody or an aptamer.6. A method for treating a subject at risk of a cardiovascular event claim 1 , comprising the steps of: contacting the blood sample with a binding partner that is specific for the IL-17, wherein the step of contacting forms an IL-17-binding partner complex,', 'detecting the IL-17-binding partner complex as a measure of a level of IL-17; and', 'comparing the level measured in said detecting step with a reference value, and, 'analyzing a blood ...

Method of treating peripheral vascular diseases using IL-18 inhibitors

The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.

Combination of sPLA2 type IIA mass and OXPL/APOB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event

The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.

Method and Pharmaceutical Composition for use in the Treatment or the Prevention of Aneurysm

The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression. 1. A method of treating or preventing aneurysm in a subject in need thereof , comprisingadministering to said subject a therapeutically effective amount of a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression.2. The method according to wherein the antagonist is an anti-IL-1 beta antibody.3. A pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression and a pharmaceutically acceptable carrier.4. The pharmaceutical composition of claim 3 , wherein the antagonist is an anti-IL-1 beta antibody. The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm.In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression.Aneurysm is a localized dilation (balloon-like bulge) of a blood vessel caused by disease or weakening of the vessel wall. Aneurysms most commonly occur in arteries at the base of the brain (the circle of Willis) and in the aorta (the main artery coming out of the heart), a so-called aortic aneurysm. The bulge in a blood vessel can burst and lead to death at any time. The larger an aneurysm becomes, the more likely it is to burst and since aneurysms naturally grow, given enough time they will inevitably reach the bursting point if undetected.Given the severe consequences ...

Methods for the Treatment of Nonalcoholic Steatohepatitis

The present invention relates to the treatment of nonalcoholic steatohepatitis (NASH), in particular to a compound that inhibits miR-21 expression for use in the treatment of nonalcoholic steatohepatitis.

METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT

The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject. 14-. (canceled)5. A method for the treatment of an inflammatory disease in a subject in need thereof , wherein said inflammatory disease is selected from the group consisting of psoriasis , inflammatory bowel disease , rheumatoid arthritis , inflammatory dermatoses and multiple sclerosis , comprising the steps of: contacting the blood sample with a binding partner that is specific for the IL-17, wherein the step of contacting forms an IL-17-binding partner complex,', 'detecting the IL-17-binding partner complex as a measure of a level of IL-17; and', 'comparing the level measured in said detecting step with a reference value, wherein said reference value is a median IL-17 level selected from the group consisting of an index from a population study, an individual or group of individuals who are unaffected by cardiovascular risk, a statistical analysis or risk prediction data of populations obtained from mathematical algorithms and computed indices of arteriovascular disease, and a sample derived from at least one subject who has been previously diagnosed or identified for a cardiovascular event, and, 'analyzing a blood sample obtained from said subject to determine whether said subject is at risk of having a cardiovascular event selected from the group consisting of sudden cardiac death, acute coronary syndrome, plaque rupture, myocardial infarction, unstable angina, a non-cardiac acute arteriovascular event, blood clot, aneurysm, aneurysm progression, stroke, and arteriovascular ischemia, by'}administering to said subject, when said IL-17 level is higher than said reference value, a therapeutically ...

METHODS FOR THE TREATMENT AND DIAGNOSIS OF ATHEROSCLEROSIS

The present invention relates to the treatment and the diagnosis of atherosclerosis, in particular to a miRNA for use in the treatment and the diagnosis of atherosclerosis. 1. A method for the treatment of arthrosclerosis in a patient in need thereof comprising a step of administering to the patienta) a compound that raises an expression level of one or more miRNAs selected from the group consisting of miR-146a, miR-302c, miR-372, and miR-624, orb) a compound that inhibits an expression level of one or more miRNAs selected from the group consisting of miR-92b, miR-126, miR-181a, miR-320c-1, miR-320c-2 and miR-1908, or orc) both a) and b).2. The method according to the further comprising a step of administering a compound that inhibits an expression level of one or more miRNAs selected from the group consisting of miR-21 claim 1 , miR-92a-1 claim 1 , miR-92a2.34-. (canceled)5. A method of identifying a patient having or at risk of having or developing atherosclerosis claim 1 , comprising the steps ofa) measuring, in a sample obtained from said patient, an expression level of at least one miRNA selected from the group consisting of miR-21, miR-92a-1, miR-92a-2, miR-92b, miR-126, miR-146a, miR-155, miR-181a, miR-302c, miR-320c-1, miR-320c-2, miR-372, miR-624 and miR-1908,b) comparing the expression level of the at least one miRNA to a control miRNA expression level, andc) detecting a differential in the expression level of the at least one miRNA and the a control miRNA expression level, wherein detection of a differential indicates that the patient has or is at risk of having or developing atherosclerosis.67-. (canceled)8. The method according to wherein the patient is afflicted with a coronary disorder claim 5 , a vascular disorder claim 5 , atherosclerotic vascular disease claim 5 , aneurysm claim 5 , stroke claim 5 , an asymptomatic coronary artery disease claim 5 , an chronic ischemic disorder without myocardial necrosis claim 5 , stable or effort angina pectoris ...

METHODS FOR THE TREATMENT AND DIAGNOSIS OF ATHEROSCLEROSIS

The present invention relates to the treatment and the diagnosis of atherosclerosis, in particular to a miRNA for use in the treatment and the diagnosis of atherosclerosis. 1. A method for the treatment of arthrosclerosis in a patient in need thereof comprising a step of administering to the patienta) a compound that raises an expression level of one or more miRNAs selected from the group consisting of miR-146a, miR-302c, miR-372, and miR-624, orb) a compound that inhibits an expression level of one or more miRNAs selected from the group consisting of miR-92b, miR-126, miR-181a, miR-320c-1, miR-320c-2 and miR-1908, or orc) both a) and b).2. The method according to further comprising a step of administering a compound that inhibits an expression level of one or more miRNAs selected from the group consisting of miR-21 claim 1 , miR-92a-1 claim 1 , miR-92a 2.34-. (canceled)5. A method of identifying a patient having or at risk of having or developing atherosclerosis claim 1 , comprising the steps ofa) measuring, in a sample obtained from said patient, an expression level of at least one miRNA selected from the group consisting of miR-21, miR-92a-1, miR-92a-2, miR-92b, miR-126, miR-146a, miR-155, miR-181a, miR-302c, miR-320c-1, miR-320c-2, miR-372, miR-624 and miR-1908,b) comparing the expression level of the at least one miRNA to a control miRNA expression level, andc) detecting a differential in the expression level of the at least one miRNA and the a control miRNA expression level, wherein detection of a differential indicates that the patient has or is at risk of having or developing atherosclerosis.67-. (canceled)8. The method according to wherein the patient is afflicted with a coronary disorder claim 5 , a vascular disorder claim 5 , atherosclerotic vascular disease claim 5 , aneurysm claim 5 , stroke claim 5 , an asymptomatic coronary artery disease claim 5 , an chronic ischemic disorder without myocardial necrosis claim 5 , stable or effort angina pectoris ...

SPLA2 CARDIOVASCULAR PROGNOSTIC AND DIAGNOSTIC MARKER

A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, comprising: 1. A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient , comprising:determining the sPLA2 activity of said patient,comparing said activity to a predetermined value,a higher sPLA2 activity of said patient as compared to said predetermined value being indicative of an increased risk of mortality or of a cardiac and/or vascular event.2. The method according to claim 1 , wherein the patient has been diagnosed as being substantially healthy with respect to atherosclerosis claim 1 , cardiac and/or vascular related diseases.3. The method according to claim 1 , wherein the patient has been diagnosed as presenting one of the following coronary disorders:asymptomatic artery coronary diseases with silent ischemia or without ischemia,chronic ischemic disorders without myocardial necrosis, selected from stable or effort angina pectoris,acute ischemic disorders without myocardial necrosis: unstable angina pectoris,ischemic disorders with myocardial necrosis, selected from ST segment elevation myocardial infarction or non-ST segment elevation myocardial infarction.4. The method according to claim 1 , wherein no onset of ischemic symptoms has been diagnosed in the patient.5. The method according to claim 1 , wherein an onset of ischemic symptoms has been diagnosed in the patient.6. The method according to claim 1 , wherein the predetermined value corresponds to a sPLA2 activity comprised in the highest two tertiles of the sPLA2 activity range of a substantially healthy individual.7. The method according to claim 1 , wherein the sPLA2 activity of the patient is higher than about 1.8 nmol/ml/min.8. The method according to claim 1 , wherein the sPLA2 activity is measured in a biological sample claim 1 , selected from a serum or a plasma sample.9. An in vitro or ex vivo method for the diagnosis of cardiac and/or ...

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OBESITY

The present invention relates to methods and pharmaceutical compositions for the treatment of obesity. In particular, the present invention relates to a method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor. 1. A method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor.2. A method for the prophylactic treatment of an obesity related disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor.3. The method of wherein the obesity related disease is selected from the group consisting of diabetes claim 2 , hypertension claim 2 , elevated plasma insulin concentrations and insulin resistance claim 2 , dyslipidemia claim 2 , and hyperlipidemia.4. A method of improving insulin sensitivity in an obese subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor. The present invention relates to methods and pharmaceutical compositions for the treatment of obesity.Obesity is a condition characterized by an excess of body fat. The prevalence of overweight and obesity is considered an important public health issue in the world. Roughly two thirds of US adults meet the criteria for overweight or obesity. Actually, obesity is an important risk factor for coronary heart disease (CHD), ventricular dysfunction, congestive heart failure, stroke, and cardiac arrhythmias. Furthermore obesity is closely associated with type 2 diabetes, metabolic syndrome and hepatic disorders such as non-alcoholic fatty liver disease. Furthermore epidemiologic evidences suggest that obesity increases the risk of cirrhosis. Thus, there is a need for treating obesity and ...

USE OF CELLS FROM ADIPOSE TISSUES TO INDUCE THE FORMATION OF A FUNCTIONAL VASCULAR NETWORK

Methods for producing a non human animal model for aortic aneurysm

The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.

Pharmaceutical composition

The present invention relates to the use of an IL-18 inhibitor for the preparation of a pharmaceutical composition intended for the treatment and/or prevention of atherosclerosis. The invention also relates to the use of a vector containing a code sequence for the IL-18 inhibitor for the preparation of a pharmaceutical composition intended for the same purpose as well as the use of cells for transfection and containing such vector.

Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

The invention relates to the use of an IL-18 inhibitor for the manufacture of a medicament for the treatment and/or prevention of atherosclerosis.

Use of adipose tissue cells for initiating the formation of a functional vascular network

Utilisation de cellules issues du tissu adipeux blanc médullaire ou extra- médullaire et notamment de la fraction stromale vasculaire extra-médullaire (FSV) et/ou d'adipocytes matures dédifférenciés quelle qu'en soit l'origine, pour induire la formation d'une vascularisation fonctionnelle.

Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases

The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.

Use of IL-18 inhibitors for the treatment and / or prevention of atherosclerosis

A b cell depleting agent for the treatment of atherosclerosis

The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.

USE OF IL-18 INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF PERIPHERAL VASCULAR DISEASES

"uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas". a presente invenção refere-se ao uso de um inibidor de il-18 na preparação de um medicamento para o tratamento e/ou prevenção de doenças vasculares periféricas. a presente invenção refere-se ainda ao uso de um inibidor de il-18 para prevenção de amputação de membros. "use of il-18 inhibitors for the treatment and / or prevention of peripheral vascular diseases." The present invention relates to the use of an il-18 inhibitor in the preparation of a medicament for the treatment and / or prevention of peripheral vascular diseases. The present invention further relates to the use of an il-18 inhibitor for preventing limb amputation.

Secretory phospholipase A2 (sPLA2) as prognostic and diagnostic marker for cardiovascular diseases

The present invention relates to a method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, comprising: - determining the sPLA2 activity of said patient, - comparing said activity to a predetermined value, a higher sPLA2 activity of said patient as compared to said predetermined value being indicative of an increased risk of mortality or of a cardiac and/or vascular event.

Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases

Il-18 inhibitors in peripheral vascular diseases of the extremities

The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.

use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis

"uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose". a invenção refere-se ao uso de um inibidor de il-18 para produção de um medicamento no tratamento e/ou prevenção da aterosclerose. "Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis". the invention relates to the use of an IL-18 inhibitor for production of a medicament in the treatment and/or prevention of atherosclerosis.

Use of IL-18 inhibitors in the manufacture of a medicament for the treatment and / or prevention of atherosclerosis

A B-cell depleting agent for the treatment of atherosclerosis

Un anticuerpo anti-CD20 para utilizarlo en el tratamiento o la prevención del infarto de miocardio. An anti-CD20 antibody for use in the treatment or prevention of myocardial infarction.

Combination of sPLA2 activity and cardiovascular risk factors OxPL / apoB for diagnosis / prognosis of a disease / cardiovascular event

Un método para identificar un sujeto que tiene o está en riesgo de tener o desarrollar una enfermedad cardiovascular y/o un evento cardiovascular, que comprende: - medir, en una muestra obtenida de dicho sujeto, por lo menos dos factores de riesgo cardiovascular: a) actividad de fosfolipasa A2 secretada (sPLA2) y b) fosfolípidos oxidados en partículas B-100 de apolipoproteína (OxPL/apoB), - combinar dichas mediciones, el valor combinado de actividad de sPLA2 y OxPL/apoB es indicador de que tiene o está en riesgo de tener o desarrollar una enfermedad cardiovascular y/o evento cardiovascular. A method to identify a subject that has or is at risk of having or developing a cardiovascular disease and / or a cardiovascular event, comprising: - measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a ) secreted phospholipase A2 activity (sPLA2) and b) apolipoprotein B-100 particles oxidized phospholipids (OxPL / apoB), - combining said measurements, the combined value of sPLA2 and OxPL / apoB activity is an indication that it has or is in risk of having or developing a cardiovascular disease and / or cardiovascular event.

USE OF IL-18 INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF PERIPHERAL VASCULAR DISEASES

Application of il-18 inhibitor for healing and/or prevention of atherosclerosis

Ovaj pronalazak se odnosi na inhibitor IL-18 za proizvodnju medikamenta za lečenje i/ili prevenciju ateroskleroze.[The invention relates to the use of an IL-18 inhibitor for the manufacture of a medicament for the treatment and/or prevention of atherosclerosis.

Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

A találmány szerinti megoldás a vaszkuláris betegségek tárgykörébetartozik. A találmány tárgya közelebbről IL-18-inhibitorok alkalmazásaatheroszklerózis kezelésére és/vagy megelőzésére. Ó The present invention is within the scope of vascular diseases. More particularly, the invention relates to the use of IL-18 inhibitors for the treatment and / or prevention of atherosclerosis. SHE

Methods for producing a non human animal model for aortic aneurysm

The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.

Tr1 cells for use in atherosclerosis

The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.

Use of IL-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases

Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten

Methods for predicting cardiovascular mortality risk

The present invention relates to a method for predicting cardiovascular mortality risk in a patient, comprising determining the level of endothelial microparticles in a blood sample obtained from said patient.

Verwendung von fettgewebezellen zur einleitung der bildung eines funktionalen gefässnetzes

COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT

The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: - measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), - combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.

Interleukin 2 chimeric constructs with targeting specificity to inflamed tissues

The present invention relates to a targeted chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a targeting moiety which binds to an oxidized protein or oxidized lipid. The targeting moiety is preferably an antibody or scFv binding specific oxidized proteins or oxidized lipids and targets the fusion protein to inflammatory tissues. The chimeric construct preferably further comprises a beta chain of the C4b-binding protein (C4BP), which is capable of forming a dimeric protein.

Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose

Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen

Masernvirus-nucleoprotein zur behandlung von atherosklerose

Use of spla2 activity for the diagnosis of a cardiovascular event

The present invention relates a method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, comprising: - determining the sPLA2 activity of said patient as a first risk marker - determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level - determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, said odds ratio compared to said predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and /or vascular event. The present invention further relates a new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2.

Use of spla2 activity for the diagnosis of a cardiovascular event

The present invention relates a method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, comprising: - determining the sPLA2 activity of said patient as a first risk marker - determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level - determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, said odds ratio compared to said predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and /or vascular event. The present invention further relates a new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2.

Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues

The present invention relates to a targeted chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a targeting moiety which binds to an oxidized protein or oxidized lipid. The targeting moiety is preferably an antibody or scFv binding specific oxidized proteins or oxidized lipids and targets the fusion protein to inflammatory tissues. The chimeric construct preferably further comprises a beta chain of the C4b-binding protein (C4BP), which is capable of forming a dimeric protein.

Tr1 cells for use in atherosclerosis

The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.

Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues

The present invention relates to a targeted chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a targeting moiety which binds to an oxidized protein or oxidized lipid. The targeting moiety is preferably an antibody or scFv binding specific oxidized proteins or oxidized lipids and targets the fusion protein to inflammatory tissues. The chimeric construct preferably further comprises a beta chain of the C4b-binding protein (C4BP), which is capable of forming a dimeric protein.

Methods and pharmaceutical compositions for the treatment of obesity

The present invention relates to methods and pharmaceutical compositions for the treatment of obesity. In particular, the present invention relates to a method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor.

Procede et dispositif de determination de caracteristiques cardiovasculaires par voie externe et leur application aux cardiopathies

Use of measles virus nucleoprotein for treating atherosclerosis

The present invention relates to the use of the measles virus nucleoprotein (NP), fragments or variants thereof for the treatment and/or the prevention of atherosclerosis.

Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados.

La presente invención se refiere a una construcción quimérica dirigida, que comprende i) un resto de interleucina 2 (IL2) y ii) un resto dirigido que se une a una proteína oxidada o a un lípido oxidado.

Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction

The present invention relates to a method for predicting the survival time of a patient suffering of myocardial infarction or the recurrence of a myocardial infarction in a patient who has suffered from a myocardial infarction comprising the steps consisting of i) determining the expression level of BAFF in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.

Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues

The present invention relates to a targeted chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a targeting moiety which binds to an oxidized protein or oxidized lipid. The targeting moiety is preferably an antibody or scFv binding specific oxidized proteins or oxidized lipids and targets the fusion protein to inflammatory tissues. The chimeric construct preferably further comprises a beta chain of the C4b-binding protein (C4BP), which is capable of forming a dimeric protein.